Why This Trader Is Worried About Jazz Pharmaceuticals

Loading...
Loading...

Christian Tharp was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.

In a special segment on the #BestOfBiotech, CMT Christian Tharp looked into several biotech stocks on his radar. Among them was Jazz Pharmaceuticals plc JAZZ, a stock about which he is worried.

Shares of Jazz have escalated over the past year (about 36 percent), or year and a half (about 119 percent). Tharp explained, “you have got yourself a test in September, you’ve got a test in November, you’ve got a test in December, you’ve got a test in March… So Jazz… the market is telling me that topside resistance matters. So, that topside resistance sits roughly around $193; we are sitting at $190 [at the time of interview].”

Related Link: How Much Further Can Jazz Pharmaceuticals Fall?

He continued, “Of course there is no guarantees, but I would say: if I was in Jazz, I’d certainly be putting it to protective stops, and looking at possibly locking in gains once we push around that $193 mark.”

Tharp concluded, “If we break through it [the $193 mark], great. Party’s on. But, if you go with probabilities, with what tends to happen… Well, what has happened every time we have approached that resistance [is] we’ve dropped. And we’ve dropped a lot. So, I’d be cautious with that one.”

Shares of Jazz Pharmaceuticals were down about 1.6 percent on Friday.

Loading...
Loading...
Posted In: BiotechHealth CareExclusivesTrading IdeasInterviewGeneralChristian Tharp
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...